An adaptive Phase I/II study to assess safety, efficacy, pharmacokinetics and pharmacodynamics of RO7112689 in healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria (PNH)
Phase of Trial: Phase I/II
Latest Information Update: 29 Sep 2017
At a glance
- Drugs RO 7112689 (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Chugai Pharmaceutical; Roche
- 25 Sep 2017 Planned End Date changed from 17 Feb 2018 to 22 Feb 2020.
- 19 Sep 2017 The trial has been completed in Netherlands.
- 17 Oct 2016 New trial record